Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Locally advanced cervical cancer, drawn from the whole corpus: 11 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether induction chemotherapy and pembrolizumab should be combined.
Access to brachytherapy and PET-CT where most patients live.
Why durvalumab (CALLA) failed where pembrolizumab succeeded.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Durvalumab added to chemoradiotherapy did not significantly improve progression-free survival in locally advanced cervical cancer.
5-year OS 80% vs 72% (HR 0.
PFS HR 0.
A milestone in how this cancer is treated.